UY36460A - Pirazolpiridinaminas - Google Patents
PirazolpiridinaminasInfo
- Publication number
- UY36460A UY36460A UY0001036460A UY36460A UY36460A UY 36460 A UY36460 A UY 36460A UY 0001036460 A UY0001036460 A UY 0001036460A UY 36460 A UY36460 A UY 36460A UY 36460 A UY36460 A UY 36460A
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- preparing
- disorder
- inflammatory
- pirazolpiridinaminas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de pirazolpiridinamina sustituida de fórmula general (I) según se los describe y define aquí, métodos para preparar dichos compuestos, compuestos intermediarios útiles para preparar dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden a dichos compuestos y el uso de dichos compuestos para elaborar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o de angiogénesis, de un trastorno inflamatorio o asociado con dolor inflamatorio,como único agente o en combinación con otros ingredientes activos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199096 | 2014-12-19 | ||
| EP15187501 | 2015-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY36460A true UY36460A (es) | 2016-07-29 |
Family
ID=54884024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001036460A UY36460A (es) | 2014-12-19 | 2015-12-18 | Pirazolpiridinaminas |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10487092B2 (es) |
| EP (1) | EP3233866B1 (es) |
| JP (1) | JP2018501250A (es) |
| KR (1) | KR20170095985A (es) |
| CN (1) | CN107250138A (es) |
| AU (1) | AU2015366417A1 (es) |
| BR (1) | BR112017013148A2 (es) |
| CA (1) | CA2971242A1 (es) |
| CL (1) | CL2017001615A1 (es) |
| CO (1) | CO2017005968A2 (es) |
| CR (1) | CR20170264A (es) |
| CU (1) | CU20170086A7 (es) |
| DO (1) | DOP2017000146A (es) |
| EA (1) | EA201791363A1 (es) |
| EC (1) | ECSP17038893A (es) |
| GT (1) | GT201700138A (es) |
| IL (1) | IL252686A0 (es) |
| MX (1) | MX2017008161A (es) |
| NI (1) | NI201700078A (es) |
| PE (1) | PE20171104A1 (es) |
| PH (1) | PH12017501133A1 (es) |
| SG (1) | SG11201704916TA (es) |
| SV (1) | SV2017005466A (es) |
| TN (1) | TN2017000258A1 (es) |
| TW (1) | TW201625648A (es) |
| UY (1) | UY36460A (es) |
| WO (1) | WO2016096721A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| WO2017081003A1 (en) * | 2015-11-12 | 2017-05-18 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyridinamines |
| SG11201907356SA (en) | 2017-02-14 | 2019-09-27 | Effector Therapeutics Inc | Piperidine-substituted mnk inhibitors and methods related thereto |
| EP3870178A4 (en) | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | CRYSTALLINE FORMS OF MNK INHIBITORS |
| CN111803476A (zh) * | 2020-08-14 | 2020-10-23 | 华中科技大学协和深圳医院 | 芬戈莫德用于抑制革兰阳性细菌活性的用途 |
| KR20230093251A (ko) | 2020-09-10 | 2023-06-27 | 프리시릭스 엔.브이. | Fap에 대한 항체 단편 |
| US20230000986A1 (en) * | 2021-07-01 | 2023-01-05 | Board Of Regents, The University Of Texas System | Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| JP4712702B2 (ja) | 2003-07-24 | 2011-06-29 | バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト | 高増殖性疾患を処置するために有用な置換されたテトラヒドロベンゾチエノピリミジンアミン化合物 |
| WO2006023843A2 (en) | 2004-08-20 | 2006-03-02 | Bayer Pharmaceuticals Corporation | Novel heterocycles |
| US8703941B2 (en) | 2011-01-10 | 2014-04-22 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| ES2592404T3 (es) * | 2012-05-21 | 2016-11-30 | Bayer Pharma Aktiengesellschaft | Benzotienopirimidinas sustituidas |
| CN104507950B (zh) | 2012-05-21 | 2017-03-22 | 拜耳医药股份有限公司 | 噻吩并嘧啶 |
| US9546153B2 (en) * | 2012-11-08 | 2017-01-17 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| CN105189518A (zh) * | 2013-02-01 | 2015-12-23 | 拜耳制药股份公司 | 取代的噻吩并吡啶和其药物用途 |
-
2015
- 2015-12-14 EA EA201791363A patent/EA201791363A1/ru unknown
- 2015-12-14 EP EP15813014.6A patent/EP3233866B1/en active Active
- 2015-12-14 PE PE2017001100A patent/PE20171104A1/es not_active Application Discontinuation
- 2015-12-14 AU AU2015366417A patent/AU2015366417A1/en not_active Abandoned
- 2015-12-14 US US15/537,694 patent/US10487092B2/en active Active
- 2015-12-14 BR BR112017013148-0A patent/BR112017013148A2/pt not_active IP Right Cessation
- 2015-12-14 KR KR1020177019615A patent/KR20170095985A/ko unknown
- 2015-12-14 TN TN2017000258A patent/TN2017000258A1/en unknown
- 2015-12-14 JP JP2017533275A patent/JP2018501250A/ja active Pending
- 2015-12-14 CA CA2971242A patent/CA2971242A1/en active Pending
- 2015-12-14 CU CUP2017000086A patent/CU20170086A7/es unknown
- 2015-12-14 CN CN201580076266.7A patent/CN107250138A/zh active Pending
- 2015-12-14 MX MX2017008161A patent/MX2017008161A/es unknown
- 2015-12-14 SG SG11201704916TA patent/SG11201704916TA/en unknown
- 2015-12-14 CR CR20170264A patent/CR20170264A/es unknown
- 2015-12-14 WO PCT/EP2015/079587 patent/WO2016096721A1/en active Application Filing
- 2015-12-18 UY UY0001036460A patent/UY36460A/es not_active Application Discontinuation
- 2015-12-18 TW TW104142845A patent/TW201625648A/zh unknown
-
2017
- 2017-06-05 IL IL252686A patent/IL252686A0/en unknown
- 2017-06-16 PH PH12017501133A patent/PH12017501133A1/en unknown
- 2017-06-16 CO CONC2017/0005968A patent/CO2017005968A2/es unknown
- 2017-06-19 DO DO2017000146A patent/DOP2017000146A/es unknown
- 2017-06-19 NI NI201700078A patent/NI201700078A/es unknown
- 2017-06-19 CL CL2017001615A patent/CL2017001615A1/es unknown
- 2017-06-19 GT GT201700138A patent/GT201700138A/es unknown
- 2017-06-19 SV SV2017005466A patent/SV2017005466A/es unknown
- 2017-06-20 EC ECIEPI201738893A patent/ECSP17038893A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180162877A1 (en) | 2018-06-14 |
| EA201791363A1 (ru) | 2018-01-31 |
| GT201700138A (es) | 2018-12-06 |
| CL2017001615A1 (es) | 2018-03-16 |
| ECSP17038893A (es) | 2017-07-31 |
| CO2017005968A2 (es) | 2017-10-20 |
| CN107250138A (zh) | 2017-10-13 |
| SV2017005466A (es) | 2018-10-02 |
| EP3233866A1 (en) | 2017-10-25 |
| CR20170264A (es) | 2017-07-21 |
| JP2018501250A (ja) | 2018-01-18 |
| AU2015366417A1 (en) | 2017-06-29 |
| PH12017501133A1 (en) | 2017-11-27 |
| WO2016096721A1 (en) | 2016-06-23 |
| MX2017008161A (es) | 2017-09-18 |
| PE20171104A1 (es) | 2017-08-07 |
| CA2971242A1 (en) | 2016-06-23 |
| NI201700078A (es) | 2017-09-22 |
| DOP2017000146A (es) | 2017-07-31 |
| SG11201704916TA (en) | 2017-07-28 |
| CU20170086A7 (es) | 2017-11-07 |
| IL252686A0 (en) | 2017-08-31 |
| TW201625648A (zh) | 2016-07-16 |
| EP3233866B1 (en) | 2021-04-21 |
| BR112017013148A2 (pt) | 2019-11-19 |
| US10487092B2 (en) | 2019-11-26 |
| KR20170095985A (ko) | 2017-08-23 |
| TN2017000258A1 (en) | 2018-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| NI201700078A (es) | Pirazolpiridinaminas | |
| UY36422A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| UY33598A (es) | Imidazopiridazinas sustituidas | |
| NI201600006A (es) | Pirazolo-piridinaminas sustituidas | |
| ECSP14013231A (es) | Imidazopiridazinas sustituidas con amino | |
| NI201500118A (es) | Imidazopiridazinas sustituidas | |
| DOP2016000118A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| CR20160433A (es) | Nuevos compuestos | |
| DOP2016000268A (es) | Compuestos de azol amidosustituidos como inhibidores de tnks1 y/o tnks2 | |
| UY37577A (es) | Dihidroimidazopiridindionas sustituidas | |
| CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| UY37444A (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso | |
| UY36983A (es) | Pirazolopiridinaminas sustituidas | |
| UY37032A (es) | Compuestos de heteroarilbenzimidazol | |
| UY34630A (es) | Imidazopiridazinas sustituidas con amino | |
| AR094934A1 (es) | Imidazopiridazinas sustituidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20220721 |